In Perioperative Immunotherapy Advances: Insights from CheckMate-77T and KEYNOTE-671, our panel delves into the following ...
Two phase 3 trials of Merck & Co's Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer immunotherapy ...
Merck & Co's Keytruda is poised to move even earlier in the treatment of patients with non-small cell lung cancer (NSCLC) after showing efficacy when used to prevent the cancer returning after surgery ...
Join your peeps for laughter, learning, and lobster rolls at B2B Forum! You'll grow your marketing and leadership skills, meet friends, and be inspired by new and different ideas. Right now, tickets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results